ライフサイエンスコーパス: fused in sarcoma

1 ue TDP-43 (TAR DNA-binding protein 43), FUS (fused in sarcoma), and alpha-synuclein toxicity in yeast

2 ing FMRP in fragile X syndrome; TDP-43, FUS (fused in sarcoma), angiogenin, and ataxin-2 in amyotroph

3 Mutations in the RNA-binding protein FUS (fused in sarcoma) are linked to amyotrophic lateral scle

4 complexity domain of the RNA-binding protein Fused in Sarcoma (FUS LC) is structurally disordered and

5 le plaques, tau neurofibrillary tangles, and fused in sarcoma (FUS) and TAR DNA-binding protein 43 (T

6 Fused in sarcoma (FUS) and TAR DNA-binding protein 43 (T

7 Mutations in RNA-binding proteins, including fused in sarcoma (FUS) and TAR DNA-binding protein 43 (T

8 ations in the RNA- and DNA-binding proteins, fused in sarcoma (FUS) and transactive response DNA-bind

9 AR DNA-binding protein of 43 kDa (TDP-43) or Fused in sarcoma (FUS) are a hallmark of amyotrophic lat

10 TAR DNA binding protein and fused in sarcoma (FUS) are both RNA processing proteins

11 Mutations in the RNA binding protein Fused in sarcoma (FUS) are estimated to account for 5-10

12 inclusions of aggregated RNA-binding protein fused in sarcoma (FUS) are hallmarks of ALS and frontote

13 TAR DNA-binding protein 43 kDa (TDP-43) and fused in sarcoma (FUS) are RNA-binding proteins that for

14 Mutations in the gene encoding Fused in Sarcoma (FUS) cause amyotrophic lateral scleros

15 Ubiquitin-positive inclusion containing Fused in Sarcoma (FUS) defines a new subtype of frontote

16 Mutations in the fused in sarcoma (FUS) gene can cause both juvenile and

17 Mutations in Fused in sarcoma (FUS) gene cause a subset of familial a

18 Dysregulation of Fused in Sarcoma (FUS) gene expression is associated wit

19 ied a missense mutation in the gene encoding fused in sarcoma (FUS) in a British kindred, linked to A

20 Fused in sarcoma (FUS) is a DNA/RNA binding protein and

21 Fused in sarcoma (FUS) is an RNA-binding protein involve

22 Fused in sarcoma (FUS) protein, linked to a number of ne

23 lasmic inclusions of the RNA-binding protein fused in sarcoma (FUS) represent one type of membraneles

24 bling fibrils formed by the LC domain of the fused in sarcoma (FUS) RNA-binding protein.

25 mplexity (LC) domains of the products of the fused in sarcoma (FUS), Ewings sarcoma (EWS), and TAF15

26 intrinsically disordered RGG/RG domains from Fused in Sarcoma (FUS), FMRP and hnRNPU.

27 Here, we demonstrate that the proto-oncogene fused in sarcoma (FUS), the chromatin remodeling ATPase

28 1), TAR DNA-binding protein 43 (TDP-43), and fused in sarcoma (FUS), we demonstrate selective degener

29 with ALS encodes the DNA/RNA-binding protein Fused in Sarcoma (FUS).

30 g protein 43 (TDP-43) or RNA-binding protein fused in sarcoma (FUS).

31 ng protein (TARDBP, also known as TDP43) and fused in sarcoma (FUS, also known as translocated in lip

32 The RNA/DNA-binding proteins fused in sarcoma (FUS; also known as TLS) and TAR DNA bi

33 Fused-In-Sarcoma (FUS) is a candidate gene for neurologi

34 abundant factors associated with the protein fused-in-sarcoma (FUS), which is mutated to cause the ne

35 rs929867 (P = 6.21 x 10(-9)), is in the gene fused-in-sarcoma (FUS), with 4 other SNPs mapping to int

36 Recently, mutations in the fused in sarcoma gene have been shown to cause familial

37 anism in NEFL (neurofilament light) and FUS (fused in sarcoma), in which mutations are known to cause

38 No fused in sarcoma mutations were found in any cases.

39 temporal atrophy (corticobasal degeneration, fused-in-sarcoma pathology).

40 nsactive response DNA binding protein 43 and fused-in-sarcoma pathology, cases of frontotemporal deme

41 42 (44%) had tau pathology and five (5%) had fused-in-sarcoma pathology.

42 or skein-like cytoplasmic inclusions in all fused in sarcoma-positive cases in which brainstem and s

43 The co-existence of fused in sarcoma-positive inclusions in both motor neuro

44 Fused in sarcoma-positive neuronal cytoplasmic and intra

45 The distribution and severity of fused in sarcoma-positive neuronal cytoplasmic inclusion

46 Cortical fused in sarcoma-positive neuronal cytoplasmic inclusion

47 e familial amyotrophic lateral sclerosis and fused in sarcoma-positive neuronal inclusions have subse

48 overlap and also significant differences in fused in sarcoma-positive pathology between the two subg

49 -nuclear localization signal (PY-NLS) of the Fused in Sarcoma protein (FUS) cause amyotrophic lateral

50 to the low complexity sequence domain of the fused in sarcoma protein, which drives the assembly of R

51 ures is a characteristic finding in sporadic fused in sarcoma proteinopathies, indicating a multisyst

52 s well as genetic and biochemical data in 14 fused in sarcoma proteinopathy cases.

53 ative for the TAR DNA binding protein 43 and fused in sarcoma proteins, mimicking the inclusions obse

54 degenerative diseases, including mutant FUS (Fused in sarcoma), SOD1 (superoxide dismutase 1), TDP43

55 Biochemically, two major fused in sarcoma species were found and shown to be more

56 nding protein translocated in liposarcoma or fused in sarcoma (TLS/FUS or FUS).

57 DR derived from the RNA granule protein FUS (fused in sarcoma) to a multivalent poly-Src homology 3 (

58 Fused in sarcoma/translated in liposarcoma (FUS/TLS) and

59 We report here 13 mutations in the fused in sarcoma/translated in liposarcoma (FUS/TLS) gen

60 TAR DNA-binding domain protein) and FUS/TLS (fused in sarcoma/translated in liposarcoma) cause a subs

61 Mutations in Fused in Sarcoma/Translocated in Liposarcoma (FUS) cause

62 rovide evidence that the RNA-binding protein fused in sarcoma/translocated in liposarcoma (FUS) is a

63 ve response DNA-binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS) a

64 tranuclear inclusions composed of TDP-43 and fused in sarcoma/translocated in liposarcoma (FUS/TLS),

65 FUS/TLS (fused in sarcoma/translocated in liposarcoma) and TDP-43

66 ociate with the RNA-binding protein Fus/TLS (fused in sarcoma/translocated in liposarcoma).

67 of the atypical RNA-binding protein fus/TLS (fused in sarcoma/translocated in sarcoma) during early f

68 oteins involved in RNA processing, including fused-in-sarcoma/translocated-in-sarcoma (FUS/TLS).

69 with a molecular mass of 43 KDa (TDP-43) and fused in sarcoma/translocation in liposarcoma (FUS/TLS),

70 ar inclusions and neurites were recorded and fused in sarcoma was biochemically analysed in both subg